# openheart Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and metaanalysis

Natalija Odanović <sup>1,2</sup> Alexandra N Schwann,<sup>2</sup> Zhiyuan Zhang,<sup>2</sup> Sohum S Kapadia,<sup>2</sup> Steffne J Kunnirickal,<sup>2</sup> Helen Parise,<sup>2</sup> Daniela Tirziu,<sup>2</sup> Ivan Ilic,<sup>1</sup> Alexandra J Lansky,<sup>3</sup> Cody G Pietras,<sup>2</sup> Samit M Shah<sup>2,4</sup>

 Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/ openhrt-2024-002852).

To cite: Odanović N, Schwann AN, Zhang Z, et al. Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and metaanalysis. Open Heart 2024;11:e002852. doi:10.1136/ openhrt-2024-002852

Received 17 July 2024 Accepted 4 September 2024

#### Check for updates

C Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Institute for Cardiovascular Diseases "Dedinje", Belgrade, Serbia

<sup>2</sup>Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA <sup>3</sup>Yale Cardiovascular Research Group, Yale Medical School, New Haven, Connecticut, USA <sup>4</sup>Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA

#### **Correspondence to**

Dr Samit M Shah; samit.shah@ yale.edu

ABSTRACT Background The prognosis of myocardial ischaemia with no obstructive coronary artery disease (INOCA) and its underlying vasomotor disorders, vasospastic angina (VSA) and microvascular angina (MVA), is not well defined. The aim of this study was to perform a systematic review and meta-analysis of studies

evaluating the long-term prognosis of patients with

INOCA. Methods We included studies evaluating the prognosis of patients with INOCA published between January 1984 and August 2023 in Medline, Embase, Web of Science and Cochrane databases. Studies were selected if they included patients who fulfilled the Coronary Vasomotor Disorders International Study Group (COVADIS) criteria for either possible or definitive VSA or MVA. The primary outcomes were composite of all-cause death and myocardial infarction (MI), and major adverse cardiovascular event (MACE) at annual intervals up to 5-year follow-up. The incidence of primary outcomes for INOCA, each INOCA endotype and by method used to determine the diagnosis was calculated using the random effects model.

Results Fifty-four studies (17 302 patients) meeting the eligibility criteria were selected. The rate of allcause death and MI with VSA was 0.7 (95% CI 0.4 to 1.0)/100 patient-years and with MVA was 1.1 (95% CI 0.7 to 1.5)/100 patient-years (p>0.05). The rate of MACE with VSA was 1.1 (95% CI 0.5 to 1.9)/100 patient-years and with MVA was 2.5 (95% CI 1.6 to 3.6)/100 patient-years (p=0.025). Patients with reduced coronary flow reserve (CFR) had higher all-cause death and MI rates than patients whose diagnosis of MVA was established based on an abnormal exercise or imaging stress test (4.7 (95% CI 2.0 to 8.4) vs 0.5 (95% CI 0.1 to 1.1) vs 1.1 (95% CI 0.5 to 2.0)/100 patient-years, p=0.001). Conclusions Overall, patients with INOCA have a low rate of MACEs, but patients with MVA, especially those with reduced CFR, have a significantly higher rate of MACE than other subgroups, although there is high

heterogeneity among the included studies. PROSPERO registration number CRD42021275070.

# WHAT IS KNOWN ON THIS TOPIC

- $\Rightarrow$  The population of patients suffering from ischaemia with no obstructive coronary artery disease (INOCA) is large and heterogeneous.
- $\Rightarrow\,$  The prognosis of patients with INOCA is variable and may not be benign.

#### WHAT THE STUDY ADDS

- $\Rightarrow$  Patients with confirmed vasospastic angina have a good long-term prognosis.
- $\Rightarrow$  Patients with microvascular angina have a worse prognosis, especially if their diagnosis is based on reduced coronary flow reserve and not stress testing alone.
- $\Rightarrow$  A focus on patient-centred outcomes is necessary both in clinical practice and in future research studies of INOCA.

# HOW THIS STUDY MIGHT AFFECT RESEARCH, **PRACTICE OR POLICY**

 $\Rightarrow$  The study will alert the medical community to the existence of poor and heterogeneous data on INOCA and especially INOCA endotypes and might stimulate researchers to study this area in a more rigorous manner.

#### INTRODUCTION Rationale

Chest pain is one of the most common presenting complaints in outpatient visits and to the emergency department.<sup>1 2</sup> Of patients who are referred for invasive coronary angiography, with or without ischaemia on non-invasive stress testing, 30-50% are found to have ischaemia and no obstructive coronary artery disease (INOCA).<sup>3–5</sup> Despite the confirmed absence of epicardial coronary artery disease (CAD), many patients experience recurrent presentations for the evaluation of chest pain.<sup>25</sup> Physiological assessment of patients with INOCA has revealed endotypes, which include epicardial







Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram showing study selection process. ACS, acute coronary syndrome; CAD, coronary artery disease; MI, myocardial infarction.

or microvascular vasospasm, coronary microvascular dysfunction or diffuse epicardial atherosclerosis in more than 75% of patients.<sup>4</sup>

While historically considered a benign syndrome, recent studies evaluating the long-term outcomes of patients with INOCA have reported a nearly four-fold increase in the incidence of mortality and major adverse cardiovascular events (MACEs) compared with patients without a diagnosis of INOCA.<sup>6–8</sup> Previous studies evaluating INOCA have included a

heterogeneous population of patients with chest pain and no obstructive CAD, patients with a specific diagnosis based on non-invasive testing and patients with a diagnosis based on invasive functional testing.<sup>9–14</sup> Therefore, there are gaps in our understanding of INOCA and uncertainty regarding differences in the incidence of adverse events based on the underlying diagnosis (vasospastic angina (VSA) or microvascular angina (MVA)) or method of diagnosis (invasive or non-invasive).



**Figure 2** Annual event rates for up to 5 years of follow-up. Forest plot showing overall estimated annual event rates with 95% CI for all-cause death. Blue diamonds with horizontal lines represent weighted point estimates of cumulative incidence rate per year with 95% CI for each outcome.

# **Objectives**

In this meta-analysis, we sought to determine the longterm prognosis of patients with INOCA stratified by both the underlying diagnosis and the method of diagnosis.

# **METHODS**

# Search strategy

We conducted a systematic review and meta-analysis of published studies using a predefined protocol registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42021275070).

We searched Medline, Embase, Web of Science and Cochrane databases using a Boolean search strategy consisting of both keywords and controlled vocabulary combining terms for INOCA including 'microvascular disease', 'coronary vasospasm', 'no obstructive coronary artery disease', 'microcirculatory' *and* 'coronary' with 'outcomes', 'major adverse events' and 'mortality'. The search was restricted to studies published in English language from January 1984 to August 2023. The complete search strategy is provided in online supplemental appendix table 1.

# Study selection criteria

Studies were selected if they reported prespecified outcomes in patients with INOCA. Only studies that reported non-obstructive CAD (<70% narrowing) using anatomical evaluation (coronary CT angiography (CTA) or invasive angiography) were selected. Additionally, studies had to meet the inclusion criteria based on the Coronary Vasomotor Disorders International Study Group (COVADIS) guidelines (online supplemental appendix tables 2, 3).<sup>15</sup> <sup>16</sup>

Studies were excluded if (1) more than 10% of study participants had CAD or prior or current acute coronary syndrome (ACS) presentations; (2) patients were diagnosed with less defined coronary abnormalities, such as diffuse (but non-obstructive) atherosclerosis, endothelial dysfunction, elevated resting flow and myocardial bridging; (3) the study included uncharacterised endotypes such as 'angiographic slow flow' that do not meet contemporary criteria for a disorder of coronary vasomotion and non-coronary surrogate testing (such as brachial artery flow mediated vasodilation, cold pressor test, handgrip test, etc).

Two investigators (NO and SSK) independently screened titles and abstracts generated by database search for eligibility criteria (figure 1). Additionally, two investigators (NO and AS) screened review records and selected relevant review articles whose bibliographies were screened for potentially relevant studies. If a study was considered potentially relevant, a full-text article was reviewed by NO and AS.

# **Data abstraction**

Two investigators (NO and AS) independently extracted the data into a Microsoft Excel spreadsheet and crosschecked for accuracy. The following fields were collected: first author first name and last name, year of publication, number of subjects, years of enrolment, study population baseline demographics including gender and cardiovascular risk factors, modality used to rule out obstructive CAD and method and modality of diagnosing specific INOCA subtype (invasive or non-invasive, specific type of test). Outcome measures were extracted with annual event rates for up to 5 years of follow-up.

# **Prespecified outcomes**

We investigated two composite outcomes: (1) all causedeath and myocardial infarction (MI); (2) MACEs, defined as a composite of cardiovascular death, MI, stroke, hospitalisation for cardiovascular causes or coronary revascularisation.

# Statistical analysis

Statistical analysis was performed by ZZ and HP. The results for each outcome were presented as incidence rates with 95% CIs.

Incidence rates from eligible studies were pooled using the DerSimonian-Laird random effects model. Freeman-Tukey double arcsine transformation was used to handle low incidence rates and to stabilise the variance. Degree of heterogeneity was estimated using I<sup>2</sup> statistics with the criteria: none '<25%', low '25–49%', moderate '50–74%', and high '75+%'. Publication bias and small study effect were assessed by degree of funnel plot asymmetry and Egger's regression test. The estimated missing studies were imputed by trim-and-fill method. Sensitivity analysis was conducted by sequentially excluding individual studies and the influence of each study on the overall incidence rate was examined. To examine sources of between-study variability, we performed subgroup analysis and random-effects meta-regression. All statistical analyses were performed using Stata V.17.0 (Stata Corp, College Station, Texas, USA).

# RESULTS

The literature search resulted in 15516 records through database searching and 954 records through review article screening (figure 1). After removing duplicate publications, 7941 records were screened for eligibility criteria.

Subgroup and Study	n/N	Follow-up (y, median)		(95% CI)
VASOSPASTIC ANGINA:				
Aboukhoudir 2016	0/29	1.5		0.000 (0.000, 0.08
Bory 1996	38/232	74		0 022 (0 016 0 03
Bott Silvorman 1092	12/50	50		0.027 (0.022, 0.06
Ecologia 1097	2/00	5.9		0.037 (0.022, 0.00
Egashira 1967	3/80			0.008 (0.003, 0.02
Figueras 2013	53/273	11.7		0.017 (0.013, 0.02
Hung 2013	6/495	8.5		0.001 (0.001, 0.00
Kashima 2001	1/85	3.9 🔳 🚽		0.004 (0.001, 0.02
Kim H 2020	12/1838	2.1		0.003 (0.002, 0.00
Lee DH 2017	47/986	4.4		0.011 (0.008, 0.01
Lee EM 2017	6/647	3.9		0 002 (0 001 0 00
Lee SV 2014	5/430	3.6		0.003 (0.001.0.00
Macumoto 2001	0/180	2.2		0.000 (0.000, 0.00
Niabimine 2001	0/100	3.5		0.000 (0.000, 0.00
Nishimiya 2021	3/232	2.8		0.005 (0.002, 0.01
Oh 2013	13/279	7.6		0.008 (0.004, 0.01
Sakata 2005	4/105	4.7 🖛		0.008 (0.003, 0.02
Schoenenberger 2016	3/142	11.3		0.002 (0.001, 0.00
Scholl	3/48	3.9		0.016 (0.005, 0.04
Seitz 2020	0/26	5		0.000 (0.000 0.02
Takatsu 2011	138/1248	11.7		0.009 (0.008, 0.01
Waters 1983	9/83	13 T		0 110 (0 050 0 10
Subgroup, DL (12 = 90.3%)	, p = 0.000)	0		0.007 (0.004, 0.01
MICROVASCULAR ANG!	NA-			
Addison 2014	2/40	18		0.028/0.007_0.00
Addison 2014	2/49	1.0	-	0.020 (0.007, 0.00
Balazs 2010	8/21	8.0 -		0.045 (0.023, 0.08
Bugiardini 2004	2/22	10.3 -		0.009 (0.002, 0.03
Chauhan 1993	0/82	3 📕 –		0.000 (0.000, 0.01
Cortigiani 2014	11/35	2.4	$\rightarrow$	0.131 (0.075, 0.21
Delcour 2009	16/48	7.4 -		0.045 (0.028, 0.07
Fragasso 2009	3/34	15 -		0 008 (0 002 0 01
Fragasso 2014	8/158	36		0.014 (0.007 0.02
Human 2010	5/100	5.0		0.000 (0.004, 0.02
Huang 2010	0/100	-		0.009 (0.004, 0.02
Kaski 1995	0/88			0.000 (0.000, 0.00
Lamendola 2010	4/155	11.4		0.002 (0.001, 0.00
Lanza 2017	27/250	16		0.007 (0.005, 0.01
Lee 2017	11/1371	3.9		0.002 (0.001, 0.00
Lin 2012	117/811	7.9 🖷		0.024 (0.020, 0.02
Liu 2020	0/77	1.3	-	0.000 (0.000, 0.03
Marks 2004	12/80	8.5	_	0.024 (0.014, 0.04
Masumoto 2001	1/88	3.2		0.005 (0.001, 0.03
Masser Gaszalaz 2010	8/24			0.000 (0.001, 0.02
Monroy-Gonzalez 2019	0/34			0.0022 (0.010, 0.04
ivisnimiya 2021	0/40	3.0		0.000 (0.000, 0.02
Radice 1995	1/30	12.3		0.003 (0.000, 0.01
Radico 2021	53/956	6.6 🗰		0.008 (0.006, 0.01
Reynolds 2021	1/208	1 🛋		0.005 (0.001, 0.02
Schoenenberger 2016	5/283	11.3		0.002 (0.001, 0.00
Schroder 2021	56/723	4.5		0.017 (0.013, 0.02
Seitz 2020	0/32	5		0.000 (0.000, 0.03
Shimokawa 2021	5/878	11 T		0.007 (0.003, 0.02
Chintonawa 2021	3/070			0.004 (0.003, 0.0
Sinniani 2003	1/44	0.4		0.004 (0.001, 0.02
Sicari 2005	6/43	1.1		0.026 (0.013, 0.08
Sicari 2009	48/87	4.3	$\rightarrow$	0.128 (0.098, 0.16
Sucato 2019	12/132	10 🗭		0.009 (0.005, 0.01
Sun 2001	1/33	7.1		0.004 (0.001, 0.02
Suzuki 2002	1/86	7.2		0.002 (0.000, 0.00
Yano 2019	3/20	5.3		0.028 (0.010 0.08
Subgroup, DL (12 = 92.5%	p = 0.000)	···· •		0.011 (0.007, 0.01
Heterogeneity between ar	oups: p = 0.13	7		
Overall, DL (l <sup>5</sup> = 91.7%, p	= 0.000)	<b>♦</b>		0.009 (0.008, 0.01

Incidence Rate (events per patient-year)

**Figure 3** Combined incidence of all-cause death and myocardial infarction (MI). Forest plot showing individual and overall estimated incidence with 95% CI for the combined outcome of all-cause death and MI. The vertical line represents the pooled incidence rate estimate for the entire INOCA cohort. The red diamonds represent the overall estimated incidence for vasospastic angina (VSA) subgroup, microvascular angina (MVA) subgroup and the overall INOCA group with 95% CI in a DerSimonian-Laird random effects model. Blue squares with horizontal lines represent weighted point estimates of incidence for each single study with 95% CI. I<sup>2</sup>, Higgins' index of heterogeneity; INOCA, ischaemia with no obstructive coronary artery disease.

A total of 54 studies met the criteria and were included in the meta-analysis. Of these, 21 studies reported outcomes for VSA and 39 for MVA. Study and patient characteristics are presented in online supplemental appendix tables 4, 5. Overall, the mean age was 56 years for VSA and 59 years for MVA; 30% of patients with VSA were female compared with 61% of patients with MVA. The mean duration of follow-up was 5.3 years for VSA and 6.6 years for MVA.

The average rate of the composite outcome of all-cause death and MI in the entire INOCA cohort was  $0.9\ (95\%$ 

Subgroup and Study	n/N	Follow-up (y, median)		Proportion (95% CI)
VASOSPASTIC ANGINA:				
Aboukhoudir 2016	0/29	1.5	•	0.000 (0.000, 0.081)
Bory 1996	95/232	7.4	-	0.055 (0.045, 0.067)
Bott-Silverman 1983	11/59	5.9		0.032 (0.018, 0.056)
Egashira 1987	1/90	4		0.003 (0.000, 0.016)
Figueras 2013	45/273	11.7		0.014 (0.011, 0.019)
Hung 2013	5/495	8.5		0.001 (0.001, 0.003)
Kashima 2001	0/65	3.9		0.000 (0.000, 0.015)
Kim H 2020	5/1929	2.1		0.001 (0.001, 0.003)
Lee D 2017	221/088	4.4		0.051 (0.045 0.058)
Lee E 2017	12/847	2.0		0.005 (0.003 0.009)
Lee C 2017	58/400	2.0		0.000 (0.000, 0.000)
Manumate 2001	0/140	3.0		0.030 (0.028, 0.047)
Masumoto 2001	471000	3.3	- L	0.000 (0.000, 0.007)
Nishimiya 2021	1//232	2.8		0.026 (0.016, 0.042)
Oh 2013	5/2/9	7.6		0.002 (0.001, 0.006)
Sakata 2005	3/105	4.7		0.006 (0.002, 0.018)
Schoenenberger 2016	(/142	11.3	-L	0.004 (0.002, 0.009)
Scholl 1988	4/48	3.9	<b>+</b> -	0.021 (0.008, 0.054)
Seitz 2020	0/26	5	• *	0.000 (0.000, 0.029)
Takatsu 2011	106/1248	11.7		0.007 (0.006, 0.009)
Waters 1983	8/63	1.3		0.098 (0.050, 0.181)
Subgroup, DL (1 <sup>2</sup> = 97.3%	, p = 0.000)		9	0.011 (0.005, 0.019)
MICROVASCULAR ANGI	NA:			
Addison 2014	38/49	1.6	≯	0.485 (0.377, 0.593)
Bugiardini 2004	1/22	10.3	-	0.004 (0.001, 0.025)
Chauhan 1993	19/82	3		0.077 (0.050, 0.117)
Delcour 2009	13/48	7.4		0.037 (0.022, 0.062)
Fragasso 2009	5/34	15		0.010 (0.004, 0.023)
Fragasso 2014	21/156	3.6	<b>*</b>	0.037 (0.025, 0.056)
Huang 2010	15/108	5	-	0.028 (0.017, 0.045)
Kaski 1995	29/99	7	+	0.042 (0.029, 0.059)
Lamendola 2010	89/155	11.4		0.050 (0.041, 0.062)
Lanza 2017	115/250	16		0.029 (0.024, 0.034)
Lee 2017	24/1371	3.9		0.004 (0.003, 0.007)
Liu 2020	0/77	13		0.000 (0.000, 0.037)
Masumoto 2001	1/88	3.3	-	0.005 (0.001, 0.026)
Mone 2023	5/2874	1		0.002 (0.001, 0.004)
Monroy Gonzalez 2010	4/24			0.015 (0.008, 0.027)
Nishimiya 2021	0/45	3.6	I.	0.000 (0.000, 0.023)
Padiao 1005	7/20	12.2	- <u>-</u>	0.010 (0.000, 0.020)
Radice 1990 Radice 2024	42/058	8.8	1	0.018 (0.008, 0.039)
Radico 2021 Devestale 2024	46/900	4	7	0.008 (0.000, 0.010)
Reynolds 2021	8/208		-	0.043 (0.023, 0.080)
Schoenenberger 2016	11/283	11.0	- L_	0.003 (0.002, 0.008)
Schroder 2021	132//23	4.5	_   =	0.041 (0.034, 0.048)
Seitz 2020	0/32	5	• _	0.000 (0.000, 0.023)
Shimokawa 2021	///678	1.1	_ +	0.103 (0.083, 0.127)
Shintani 2003	0/44	6.4	-	0.000 (0.000, 0.013)
Sicari 2005	3/43	7.1	•	0.010 (0.003, 0.028)
Sicari 2009	48/87	4.3		0.128 (0.098, 0.166)
Sucato 2019	34/132	10	•	0.026 (0.018, 0.036)
Sun 2001	1/33	7.1		0.004 (0.001, 0.024)
Suzuki 2002	5/86	7.2		0.008 (0.003, 0.019)
Yang 2019	9/20	5.3		0.085 (0.045, 0.154)
Subgroup, DL (1 <sup>2</sup> = 96.7%	, p = 0.000)		<b>◊</b>	0.025 (0.016, 0.036)
Heterogeneity between gr	oups: p = 0.0	25		
Overall, DL (l <sup>2</sup> = 97.0%, p	= 0.000)		•	0.019 (0.013, 0.025)
			U .1 .2 .3 .4	+ • • • • • • • •
		Incio	ience Rate (events per patien	t-year)

**Figure 4** Combined incidence of major adverse cardiovascular event (MACE). Forest plot showing individual and overall estimated incidence with 95% CI for the combined outcome of MACE consisting of cardiovascular death, myocardial infarction, stroke, hospitalisation for cardiovascular causes and coronary revascularisation. The vertical line represents the pooled incidence rate estimate. The red diamonds represent the overall estimated incidence for vasospastic angina (VSA) subgroup, microvascular angina (MVA) subgroup and the overall INOCA group with 95% CI in a DerSimonian-Laird random effects model. Blue squares with horizontal lines represent weighted point estimates of incidence for each single study with 95% CI. I<sup>2</sup>, Higgins' index of heterogeneity; INOCA, ischaemia with no obstructive coronary artery disease.

CI 0.6 to 1.2)/100 patient-years ( $I^2=91.7\%$ , p<0.01). The average rate of the composite outcome of MACE was 1.9 (95% CI 1.3 to 2.5)/100 patient-years ( $I^2=97.0\%$ , p<0.01). Annual rates up to 5 years of all-cause death are shown in figure 2.

# Vasospastic angina

Twenty-one studies (7523 patients) were included for VSA (online supplemental appendix table 4). All studies ruled out obstructive CAD with coronary angiography. One study used the clinical diagnosis of VSA, 16 studies established the diagnosis of VSA invasively and 4 studies used either clinical or invasive criteria for subject inclusion. Among studies using invasive criteria, 6 used acetyl-choline only, 12 used ergonovine or methylergonovine only, and 2 used either. Six studies used a cut-off  $\geq$ 90% lumen reduction by visual assessments to define spasm and the remaining 15 studies used a cut-off that was lower than that or multiple cutoffs. Definitive VSA based

on the COVADIS criteria was diagnosed in 5 studies and possible in the remaining 16 studies. The combined incidence of all-cause death and MI was 0.7 (95% CI 0.4 to 1.0)/100 patient-years (I<sup>2</sup>=90.3%, p<0.01) (figure 3) and a combined incidence of MACE was 1.1 (95% CI 0.5 to 1.9)/100 patient-years (I<sup>2</sup>=97.3%, p<0.01) (figure 4). There was no difference in either of the two composite outcomes when we compared studies defining spasm as  $\geq$ 90% lumen reduction versus studies using lower a cutoff or when we compared studies with definitive versus possible VSA by the COVADIS criteria (p>0.05) (online supplemental appendix tables 7, 8).

# Coronary microvascular angina

Thirty-nine studies (9779 patients) met the inclusion criteria for coronary MVA (online supplemental appendix table 5). One study used CTA, two studies used either CTA or angiography, and the remaining studies relied exclusively on coronary angiography to rule

# **Open Heart**

out obstructive CAD. The diagnosis of suspected MVA was present based on positive stress tests in 20 studies, while 17 studies had evidence of impaired coronary microvascular function: 11 had impaired coronary flow reserve (CFR), 5 had microvascular spasm and 1 study had an abnormal index of microcirculatory resistance. Two studies included participants meeting both criteria for suspected and definitive MVA but did not provide outcomes separately for the groups. The combined incidence of all-cause death and MI was 1.0 (95% CI 0.6 to 1.4)/100 patient-years (I<sup>2</sup>=92.2%, p<0.01) (figure 3) and a combined incidence of MACE was 2.5 (95% CI 1.6 to 3.6)/100 patient-years (I<sup>2</sup>=96.7%, p<0.01) (figure 4).

Patients whose diagnosis was established based on a positive stress test of any type had 5.7 times lower rates of all-cause death and MI (0.5 (95% CI 0.1 to 1.1) and 1.1 (95% CI 0.5 to 2.0) for exercise and imaging, respectively) than patients who had an abnormal CFR (4.7 (95% CI 2.0 to 8.4), p<0.01). When the outcomes were expanded to MACE, this trend persisted, but without statistical significance. The incidence of MACE was higher in the MVA cohort compared with the incidence in patients with VSA (2.5 (95% CI 1.6 to 3.6) vs 1.1 (95% CI 0.5 to 1.9), p=0.025) (online supplemental appendix tables 7, 8).

## **Publication bias**

We observed no funnel plot asymmetry for all-cause death and MI (online supplemental appendix figure 1, Egger's test: p=0.154), but the presence of funnel plot asymmetry for MACE (online supplemental appendix figure 2, Egger's test: p=0.022) indicated the presence of publication bias. A sensitivity analysis was performed with the leave-one-out method. There were no studies that substantially influenced the overall incidence estimate (online supplemental appendix figure 3, 4).

#### Additional analyses

We included continuous variables hypertension, hyperlipidaemia and diabetes in the meta-regression to further characterise between-study variance. On average, patients with hypertension, hyperlipidaemia or diabetes had higher MACE rates (p<0.01). For the incidence of all-cause death and MI, the between-study variance can be explained by hypertension (20.2%), hyperlipidaemia (16.1%) and diabetes (28.2%); for the incidence of MACE, the between-study variance can be explained by hypertension (38.6%) and diabetes (18.4%) via the  $R^2$  statistics. However, high residual variation due to between-study heterogeneity remained (I<sup>2</sup>>90%), which may be due to other covariates or uncharacterised factors (online supplemental appendix tables 9,10).

#### DISCUSSION

In this meta-analysis, we examined the incidence of clinical outcomes in patients with INOCA using contemporary criteria to define different INOCA endotypes. We found that the aggregate incidence of adverse events was low, but patients with MVA had a worse long-term prognosis than those with VSA. This was especially true for patients with a reduced CFR, who had a worse prognosis than those with an empiric diagnosis based on stress testing.

Prior studies and meta-analyses of long-term outcomes in patients without obstructive CAD included clinical presentations such as ACS (myocardial infarction with non-obstructive coronary arteries (MINOCA)) and stable angina but also possibly a large portion of relatively healthy subjects.<sup>17</sup> <sup>18</sup> A more recent meta-analysis attempted to limit study inclusion to those enrolling only symptomatic stable patients.9 Our meta-analysis of patients with INOCA is the first to limit study inclusion based on contemporary COVADIS criteria and to compare outcomes of VSA and coronary MVA. Our results for the overall cohort are concordant with Radico *et al*<sup>*t*</sup> (pooled incidence of all-cause death and MI for the entire INOCA cohort in our meta-analysis of 0.9 (95% CI 0.6 to 1.2)/100 patient-years vs 0.98 (95% CI 0.77 to 1.19)/100 patient-years in their meta-analysis).

A meta-analysis of 11 studies by Gdowski *et al* found a HR of 3.62 for mortality in patients with reduced CFR compared with patients without reduced CFR.<sup>6</sup> Although we were able to include only 2 of the 11 studies from that meta-analysis based on the COVADIS inclusion criteria, we also concluded that a reduced CFR carries 5.7 times higher risk of all-cause death and MI compared with positive stress test alone. This is in concordance with the existing literature showing that abnormal CFR leads to worse outcomes in patients with non-obstructive coronary artery disease.<sup>19 20</sup>

In a subgroup analysis done by Radico *et al*, the presence or absence of myocardial ischaemia on stress testing did not affect the rates of all-cause death and MI. However, once stratified by type of stress test, Radico *et al* found that those with ischaemia on plain exercise treadmill tests had significantly lower incidences of adverse events compared with those with ischaemia on imaging stress tests (0.56 (95% CI 0.23 to 0.88) vs 1.52 (95% CI 0.45 to 2.58), p=0.02). By contrast, in our analysis the incidence of all-cause death and MI in studies with positive exercise stress test versus stress tests with imaging was not significantly different (0.5 (95% CI 0.1 to 1.1) vs 1.1 (95% CI 0.5 to 2.0) (p>0.05).

While the overall rates of MACE are low for both MVA and VSA, affected patients have a high burden of symptoms, impaired quality of life and increased healthcare costs.<sup>21</sup> Patient-reported outcomes have been seldom studied in detail in the trials of INOCA. Future prospective studies of outcomes in patients with INOCA should include patient reported outcomes as well as 'hard' endpoints with standardised definitions of endotypes to further characterise the long-term prognosis of coronary vasomotor disorders. To address current gaps in our knowledge, the DISCOVER INOCA prospective multicentre registry (NCT05288361) is currently ongoing, which will include standardised assessments of patient-reported outcomes, angiography, physiology and intravascular imaging.

# Meta-analysis

#### Limitations

Our meta-analysis has limitations including high heterogeneity among the included studies, many of which were single centre studies. The overall quality of data is poor and few studies fulfil the criteria for 'definitive', while most can only be classified as 'possible' VSA or MVA. Additionally, it is likely that an unknown burden of atherosclerotic coronary artery disease beyond angiographic assessment existed; therefore, the contribution of coronary artery disease to the reported associations remains incompletely characterised.

#### **CONCLUSIONS**

Overall, patients with INOCA have a low rate of MACE, although there is heterogeneity in outcomes based on the underlying phenotype. Patients with VSA have a relatively benign long-term prognosis, whereas patients with MVA have a significantly higher rate of MACE at longterm follow-up. Among patients with MVA, those with reduced CFR had higher rates of all-cause death and MI.

Contributors NO: Conceptualisation, investigation, writing—original draft. ANS: Investigation. ZZ: Statistical analysis. SSK: Investigation. SJK: Investigation. HP: Statistical analysis. DT: Conceptualisation, writing—review and editing. II: Writing—review and editing. AJL: Conceptualisation, writing—review and editing. CGP: Writing—review and editing. SMS: Conceptualisation, investigation, writing original draft, supervision. NO and SMS are the guarantors.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** N0 has nothing to disclose. AAS has nothing to disclose. ZZ has nothing to disclose. SK has nothing to disclose. SK has nothing to disclose. HP has nothing to disclose. DT has nothing to disclose. II receives investigatorinitiated research support from Abbott Vascular. AJL receives institutional grants and research support from Abbott Vascular, Sinomed, TriReme Medical, Abiomed and consulting fees from MedAlliance, Abiomed and Boston Scientific. CGP has nothing to disclose. SMS receives investigator-initiated research support from Abbott Vascular, Sinomed and Drug Administration and Women's Health Research at Yale.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID iD**

Natalija Odanović http://orcid.org/0000-0003-0343-6195

#### REFERENCES

- 1 Ruigómez A, Rodríguez LAG, Wallander M-A, *et al.* Chest pain in general practice: incidence, comorbidity and mortality. *Fam Pract* 2006;23:167–74.
- 2 Safdar B, Dziura J, Bathulapalli H, *et al.* Chest pain syndromes are associated with high rates of recidivism and costs in young United States Veterans. *BMC Fam Pract* 2015;16:88.
- 3 Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010;362:886–95.
- 4 Lee B-K, Lim H-S, Fearon WF, *et al.* Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. *Circulation* 2015;131:1054–60.
- 5 DeMaria AN, Lee G, Amsterdam EA, *et al.* The anginal syndrome with normal coronary arteries. Etiologic and prognostic considerations. *JAMA* 1980;244:826–8.
- 6 Gdowski MA, Murthy VL, Doering M, et al. Association of Isolated Coronary Microvascular Dysfunction With Mortality and Major Adverse Cardiac Events: A Systematic Review and Meta-Analysis of Aggregate Data. JAHA 2020;9:e014954.
- 7 Herscovici R, Sedlak T, Wei J, *et al.* Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk? *JAHA* 2018;7:e008868.
- 8 Brainin P, Frestad D, Prescott E. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: A systematic review and meta-analysis. *Int J Cardiol* 2018;254:1–9.
- 9 Radico F, Zimarino M, Fulgenzi F, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. *Eur Heart J* 2018;39:2135–46.
- 10 Jespersen L, Hvelplund A, Abildstrøm SZ, *et al.* Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. *Eur Heart J* 2012;33:734–44.
- 11 Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150–6.
- 12 Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. *Circulation* 2014;129:2518–27.
- 13 Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation* 2015;131:19–27.
- 14 Lee JM, Jung J-H, Hwang D, et al. Coronary Flow Reserve and Microcirculatory Resistance in Patients With Intermediate Coronary Stenosis. J Am Coll Cardiol 2016;67:1158–69.
- 15 Beltrame JF, Crea F, Kaski JC, *et al.* International standardization of diagnostic criteria for vasospastic angina. *Eur Heart J* 2017;38:2565–8.
- 16 Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol 2018;250:16–20.
- 17 Huang F-Y, Huang B-T, Lv W-Y, et al. The Prognosis of Patients With Nonobstructive Coronary Artery Disease Versus Normal Arteries Determined by Invasive Coronary Angiography or Computed Tomography Coronary Angiography: A Systematic Review. *Medicine* (*Baltimore*) 2016;95:e3117.
- 18 Wang ZJ, Zhang LL, Elmariah S, et al. Prevalence and Prognosis of Nonobstructive Coronary Artery Disease in Patients Undergoing Coronary Angiography or Coronary Computed Tomography Angiography: A Meta-Analysis. *Mayo Clin Proc* 2017;92:329–46.
- 19 Boerhout CB, de Waard G de W, Lee JM, et al. Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease; from the multicentre international ILIAS registry. *EuroIntervention* 2022;18:719–28.
- 20 AlBadri A, Bairey Merz CN, Johnson BD, et al. Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in Women. J Am Coll Cardiol 2019;73:684–93.
- 21 Ahmad A, Corban MT, Moriarty JP, *et al.* Coronary Reactivity Assessment Is Associated With Lower Health Care-Associated Costs in Patients Presenting With Angina and Nonobstructive Coronary Artery Disease. *Circ Cardiovasc Interv* 2023;16:e012387.